Cheng‐Ta Yang

9.9k total citations · 2 hit papers
283 papers, 6.4k citations indexed

About

Cheng‐Ta Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Cheng‐Ta Yang has authored 283 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Pulmonary and Respiratory Medicine, 119 papers in Oncology and 55 papers in Molecular Biology. Recurrent topics in Cheng‐Ta Yang's work include Lung Cancer Treatments and Mutations (108 papers), Colorectal Cancer Treatments and Studies (46 papers) and Lung Cancer Diagnosis and Treatment (44 papers). Cheng‐Ta Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (108 papers), Colorectal Cancer Treatments and Studies (46 papers) and Lung Cancer Diagnosis and Treatment (44 papers). Cheng‐Ta Yang collaborates with scholars based in Taiwan, United States and China. Cheng‐Ta Yang's co-authors include Gur P. Kaushal, David M. Jablons, Varsha Kaushal, Liang You, Ping‐Chih Hsu, Sudhir V. Shah, Kuo‐Chin Kao, Chung-Chi Huang, Li‐Fu Li and Christian Herzog and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Cheng‐Ta Yang

270 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

2022 238 citations Cheng‐Ta Yang et al. Journal of Clinical Oncology profile →
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

2023 114 citations Yu‐Hsiang Juan, Cheng‐Ta Yang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheng‐Ta Yang Taiwan	42	2.5k	2.0k	1.8k	821	666	283	6.4k
Yan Xu China	36	1.8k 0.7×	1.8k 0.9×	1.7k 0.9×	590 0.7×	742 1.1×	432	5.9k
Lin Li China	34	2.7k 1.1×	2.3k 1.1×	2.1k 1.2×	467 0.6×	1.1k 1.7×	210	5.9k
Noboru Hattori Japan	40	2.8k 1.1×	1.1k 0.6×	1.1k 0.6×	609 0.7×	509 0.8×	295	5.6k
Pingfu Fu United States	50	2.0k 0.8×	2.5k 1.2×	2.4k 1.3×	749 0.9×	1.1k 1.6×	319	8.2k
David‐Alexandre Trégouët France	45	1.2k 0.5×	948 0.5×	1.9k 1.0×	818 1.0×	675 1.0×	189	6.8k
Wei Chen China	47	1.3k 0.5×	2.4k 1.2×	3.6k 1.9×	639 0.8×	1.6k 2.4×	272	8.2k
Nicholas Syn Singapore	40	1.9k 0.7×	2.0k 1.0×	1.8k 1.0×	1.1k 1.3×	926 1.4×	225	6.6k
Aliya N. Husain United States	48	4.6k 1.8×	1.5k 0.8×	2.5k 1.4×	978 1.2×	721 1.1×	250	9.4k
Gang Xu China	39	940 0.4×	1.5k 0.8×	2.0k 1.1×	697 0.8×	552 0.8×	218	8.0k
Fiorella Calabrese Italy	45	2.0k 0.8×	1.6k 0.8×	1.6k 0.9×	1.4k 1.7×	585 0.9×	292	8.4k

Countries citing papers authored by Cheng‐Ta Yang

Since Specialization

Citations

This map shows the geographic impact of Cheng‐Ta Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng‐Ta Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng‐Ta Yang more than expected).

Fields of papers citing papers by Cheng‐Ta Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng‐Ta Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng‐Ta Yang. The network helps show where Cheng‐Ta Yang may publish in the future.

Co-authorship network of co-authors of Cheng‐Ta Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng‐Ta Yang. A scholar is included among the top collaborators of Cheng‐Ta Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng‐Ta Yang. Cheng‐Ta Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsu, Chih‐Hung, Li‐Chung Chiu, Chih‐Hsi S. Kuo, et al.. (2025). Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis. Oncology Letters. 29(4). 1–12. 1 indexed citations

Qian, Xianling, Yilei Zhang, Bin Qian, et al.. (2025). Multi-regional radiomics for predicting microvascular invasion and lymph node metastasis in intrahepatic cholangiocarcinoma. Clinical Radiology. 88. 106979–106979. 1 indexed citations

Dong, Yonghai, et al.. (2024). Visual analysis of global hemorrhagic fever with renal syndrome research from 1980 to 2022: Based on CiteSpace and VOSviewer. Medicine. 103(13). e37586–e37586.

Lu, Chun‐Wei, Chun‐Bing Chen, Tsu‐Man Chiu, et al.. (2024). Consensus of the Taiwanese dermatological association and Taiwan Lung Cancer Society on the prevention and management of tyrosine kinase inhibitor-related skin toxicities in patients with non-small cell lung cancer: An updated version incorporating Taiwanese treatment experience. Journal of the Formosan Medical Association. 124(5). 402–412.

Huang, Chi‐Hsien, Chin‐Chou Wang, Fu‐Tsai Chung, et al.. (2023). Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Scientific Reports. 13(1). 20323–20323. 8 indexed citations

Yang, James Chih‐Hsin, Jong Seok Lee, Yun Fan, et al.. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9000–LBA9000. 50 indexed citations

Hsu, Ping‐Chih, John Wen‐Cheng Chang, Chen‐Yang Huang, et al.. (2022). Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease. 16. 2673712059–2673712059. 10 indexed citations

Chang, John Wen‐Cheng, Chen‐Yang Huang, Yueh‐Fu Fang, et al.. (2022). Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers. 14(4). 977–977. 11 indexed citations

Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chin‐Chou Wang, et al.. (2022). Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers. 14(2). 316–316. 7 indexed citations

10.

Kuo, Chih‐Hsi S., Chin‐Chou Wang, John Wen‐Cheng Chang, et al.. (2021). A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer. 21(1). 309–309. 5 indexed citations

11.

Chiu, Li‐Chung, Ping‐Chih Hsu, Tzung‐Hai Yen, et al.. (2021). Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina. 57(11). 1160–1160. 3 indexed citations

12.

Huang, Chung‐Guei, Avijit Dutta, Ching‐Tai Huang, et al.. (2021). Relative COVID-19 Viral Persistence and Antibody Kinetics. Pathogens. 10(6). 752–752. 6 indexed citations

13.

Wang, Chin‐Chou, Chien‐Ying Liu, Chih‐Liang Wang, et al.. (2020). Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer. Thoracic Cancer. 11(6). 1541–1549. 28 indexed citations

14.

Zhang, Fan, Yanping Gong, Qian Huang, et al.. (2019). The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. SHILAP Revista de lepidopterología. 2 indexed citations

15.

Hsu, Ping‐Chih, Chun‐Chieh Wang, Chen‐Te Wu, et al.. (2019). Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study. Thoracic Cancer. 10(8). 1683–1691. 4 indexed citations

16.

Kuo, Chih‐Hsi S., Chi‐Hsien Huang, Chien‐Ying Liu, et al.. (2019). Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Targeted Oncology. 14(4). 433–440. 10 indexed citations

17.

Hung, Ming‐Szu, Yi-Chuan Chen, Paul-Yann Lin, et al.. (2019). Cul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10. Cancers. 11(5). 618–618. 21 indexed citations

18.

Hsu, Ping‐Chih, Zhen Huang, Yi‐Lin Yang, et al.. (2018). Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of Cellular and Molecular Medicine. 22(6). 3073–3085. 26 indexed citations

19.

Chang, Chih-Hao, Chung-Shu Lee, Shih‐Hong Li, et al.. (2017). Feasibility of Radial Endobronchial Ultrasound-Guided Bronchoscopic Cryobiopsy without Fluoroscopy for Lung Parenchymal Lesions. Canadian Respiratory Journal. 2017. 1–5. 7 indexed citations

20.

Yang, Cheng‐Ta, et al.. (2015). A Meta-Analysis of Changes and Determinants of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients undergoing Chemotherapy. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact